Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin*,†,§,∥ †Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States ‡Laboratory for Advanced Studies of Membrane Proteins, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

New Developments in Liposomal Drug Delivery.

The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

TFOS DEWS II Management and Therapy Report

Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review.

Particle size and physical state of the lipid phase are major factors influencing the permanence of lipid dispersions. Nanostructured lipid carriers (NLC) are a delivery system in which partial-crystallized lipid particles with mean radii ≤ 100 nm are dispersed in an aqueous phase containing emulsifier(s), as a potential delivery system may have some advantages in certain circumstances when compared with other colloidal carriers. NLC are a useful nutraceutical delivery system with high drug loading, encapsulation efficiency and stability. They may increase, bioavailability and stability of bioactive compounds, and shelf-life, consumer acceptability, functionality, nutritional value and safety of food systems, and provide controlled release of encapsulated materials. In this review, beneficial aspects of NLC are presented and valuable information about ingredients, production methods, structure and characteristics of them provided. Moreover, potential applications and disadvantages of NLC as emerging delivery system in food science are introduced. Industrial relevance With the increasing public perception of a strong correlation between food and disease prevention, producers are trying to enrich staple foods and beverages with nutraceuticals and produce functional foods. Nonetheless, fortification of aqueous-based food with many of nutraceuticals is greatly limited owing to their poor water-solubility, chemical instability, and low bioavailability. NLC are a novel nanocarrier that may dispel these limitations, combine the advantages of other lipid nanocarriers and avoid some of their disadvantages. They may be suitable for application within foods and transparent/opaque beverages.

Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules

Nanostructured lipid carriers: Promising drug delivery systems for future clinics.

Polymeric micelles (PMs) self-assembled by amphiphilic block copolymers have been used as promising nanocarriers for tumor-targeted delivery due to their favorable properties, such as excellent biocompatibility, prolonged circulation time, favorable particle sizes (10–100 nm) to utilize enhanced permeability and retention effect and the possibility for functionalization. However, PMs can be easily destroyed due to dilution of body fluid and the absorption of proteins in system circulation, which may induce drug leakage from these micelles before reaching the target sites and compromise the therapeutic effect. This paper reviewed the factors that influence stability of micelles in terms of thermodynamics and kinetics consist of the critical micelle concentration of block copolymers, glass transition temperature of hydrophobic segments and polymer–polymer and polymer–cargo interaction. In addition, some effective strategies to improve the stability of micelles were also summarized.

Factors affecting the stability of drug-loaded polymeric micelles and strategies for improvement

To investigate the possibility of liquid proliposomes being carriers for oral delivery, nimodipine liquid proliposomes-based soft capsules (NPSC) were prepared. Nimodipine proliposomes were characterized by transmission electron microscopy (TEM), conversion rate from proliposomes to liposomes, entrapment efficiency, particle size, and zeta potential. Accelerated stability testing of NPSC was carried out for 3 months at 40 ± 2°C, 75 ± 5% RH. The concentration of nimodipine in plasma of New Zealand rabbits of NPSC, nimodipine soft capsules, and hydrated liposomes was studied. Results showed that nimodipine proliposomes were automatically converted into liposomes when exposed to a water phase in 30 s. The average diameter was 378.6 ± 26.5 nm in distilled water with entrapment efficiency (EE%) of 84.7 ± 5.9%, while the average diameter was 316.9 ± 34.6 nm in 0.1 M hydrochloric acid solution with EE% of 72.8 ± 4.7%. Accelerated stability test showed that there was no change in drug content, particle size, and EE% except for a decrease in dissolution of nimodipine. In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively. Nimodipine-hydrated liposomes presented similar pharmacokinetic parameters compared with NPSC. Results suggested that NPSC offered a potential way to improve oral delivery of nimodipine.

/pdf/liquid-proliposomes-of-nimodipine-drug-delivery-system-1amjvixs7a.pdf

Liquid Proliposomes of Nimodipine Drug Delivery System: Preparation, Characterization, and Pharmacokinetics

Biofunctional polymer-lipid hybrid high density lipoprotein-mimicking nanoparticles loading anti-miR155 for combined antiatherogenic effects on macrophages

https://pubs.acs.org/doi/pdf/10.1021/acs.biomac.9b00091

Jianping Liu

Papers

Factors affecting the stability of drug-loaded polymeric micelles and strategies for improvement

Liquid Proliposomes of Nimodipine Drug Delivery System: Preparation, Characterization, and Pharmacokinetics

Biofunctional polymer-lipid hybrid high density lipoprotein-mimicking nanoparticles loading anti-miR155 for combined antiatherogenic effects on macrophages

ATP-Responsive Low-Molecular-Weight Polyethylenimine-Based Supramolecular Assembly via Host–Guest Interaction for Gene Delivery

Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol